Prognostic Value and Oncogenic Landscape of TP53 Alterations in Adult and Pediatric T-ALL

Letter to Blood| March 16, 2023 Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL Clinical Trials & Observations Mathieu Simonin, Mathieu Simonin 1Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Université de Paris Cité, Paris, France2Institut Necker-Enfants Malades, INSERM U1151, Paris, France3Department of Pediatric Hematology and Oncology, Assistance Publique-Hôpitaux de Paris, Armand Trousseau Hospital, Sorbonne Université, Paris, France https://orcid.org/0000-0002-0448-8811 Search for other works by this author on: This Site PubMed Google Scholar Guillaume P. Andrieu, Guillaume P. Andrieu 1Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Université de Paris Cité, Paris, France2Institut Necker-Enfants Malades, INSERM U1151, Paris, France https://orcid.org/0000-0003-0289-4952 Search for other works by this author on: This Site PubMed Google Scholar Rudy Birsen, Rudy Birsen 4Department of Hematology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris, France5Institut Cochin, INSERM U1016, Paris, France Search for other works by this author on: This Site PubMed Google Scholar Marie Balsat, Marie Balsat 6Hospices Civils de Lyon, Service d'Hématologie Clinique, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France Search for other works by this author on: This Site PubMed Google Scholar Guillaume Hypolite, Guillaume Hypolite 1Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Université de Paris Cité, Paris, France2Institut Necker-Enfants Malades, INSERM U1151, Paris, France Search for other works by this author on: This Site PubMed Google Scholar Lucien Courtois, Lucien Courtois 1Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Université de Paris Cité, Paris, France2Institut Necker-Enfants Malades, INSERM U1151, Paris, France Search for other works by this author on: This Site PubMed Google Scholar Carlos Graux, Carlos Graux 7CHU UCLouvain Namur-Godinne, service d’Hématologie, Yvoir, Belgium Search for other works by this author on: This Site PubMed Google Scholar Nathalie Grardel, Nathalie Grardel 8Laboratory of Hematology, CHRU Lille, Lille, France9INSERM U1172, Lille, France https://orcid.org/0000-0001-6573-1312 Search for other works by this author on: This Site PubMed Google Scholar Jean-Michel Cayuela, Jean-Michel Cayuela 10Laboratory of Hematology and EA3518, Saint-Louis University Hospital, Université de Paris Cité, Paris, France Search for other works by this author on: This Site PubMed Google Scholar Françoise Huguet, Françoise Huguet 11Department of Hematology, CHRU-Institut Universitaire de Cancer Toulouse-Oncopole, Toulouse, France https://orcid.org/0000-0002-9576-8578 Search for other works by this author on: This Site PubMed Google Scholar Yves Chalandon, Yves Chalandon 12Division of Hematology, Department of Oncology, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland13Swiss Group for Clinical Cancer Research, Bern, Switzerland https://orcid.org/0000-0001-9341-8104 Search for other works by this author on: This Site PubMed Google Scholar Yannick Le Bris, Yannick Le Bris 14Hematology Biology, Nantes University Hospital and Nantes-Angers Cancer and Immunology Research Center, Nantes, France https://orcid.org/0000-0002-0095-6999 Search for other works by this author on: This Site PubMed Google Scholar Elizabeth Macintyre, Elizabeth Macintyre 1Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Université de Paris Cité, Paris, France3Department of Pediatric Hematology and Oncology, Assistance Publique-Hôpitaux de Paris, Armand Trousseau Hospital, Sorbonne Université, Paris, France https://orcid.org/0000-0003-0520-0493 Search for other works by this author on: This Site PubMed Google Scholar Virginie Gandemer, Virginie Gandemer 15Department of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France https://orcid.org/0000-0002-4991-233X Search for other works by this author on: This Site PubMed Google Scholar Arnaud Petit, Arnaud Petit 3Department of Pediatric Hematology and Oncology, Assistance Publique-Hôpitaux de Paris, Armand Trousseau Hospital, Sorbonne Université, Paris, France https://orcid.org/0000-0001-8363-1622 Search for other works by this author on: This Site PubMed Google Scholar Philippe Rousselot, Philippe Rousselot 16Department of Hematology, Centre Hospitalier de Versailles, Le Chesnay, France17Université Paris-Saclay, Communauté Paris-Saclay, France https://orcid.org/0000-0003-3238-4494 Search for other works by this author on: This Site PubMed Google Scholar André Baruchel, André Baruchel 18Department of Pediatric Hematology and Immunology, Assistance Publique-Hôpitaux de Paris, Robert Debré Hospital, Université de Paris Cité, Paris, France Search for other works by this author on: This Site PubMed Google Scholar Didier Bouscary, Didier Bouscary 4Department of Hematology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris, France5Institut Cochin, INSERM U1016, Paris, France Search for other works by this author on: This Site PubMed Google Scholar Olivier Hermine, Olivier Hermine 19Department of Hematology, INSERM U1163, IMAGINE Institute, Paris University, Necker Hospital, Paris, France Search for other works by this author on: This Site PubMed Google Scholar Nicolas Boissel, Nicolas Boissel 20Université Paris Cité, Institut de Recherche Saint-Louis, URP-3518, Publique-Hôpitaux de Paris, Saint-Louis University Hospital, Paris, France https://orcid.org/0000-0003-2091-7927 Search for other works by this author on: This Site PubMed Google Scholar Vahid Asnafi Vahid Asnafi 1Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Université de Paris Cité, Paris, France2Institut Necker-Enfants Malades, INSERM U1151, Paris, France Search for other works by this author on: This Site PubMed Google Scholar Blood (2023) 141 (11): 1353–1358. https://doi.org/10.1182/blood.2022017755 Article history Submitted: July 13, 2022 Accepted: December 21, 2022 First Edition: January 4, 2023 Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Request Permissions Cite Icon Cite Search Site Citation Mathieu Simonin, Guillaume P. Andrieu, Rudy Birsen, Marie Balsat, Guillaume Hypolite, Lucien Courtois, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Françoise Huguet, Yves Chalandon, Yannick Le Bris, Elizabeth Macintyre, Virginie Gandemer, Arnaud Petit, Philippe Rousselot, André Baruchel, Didier Bouscary, Olivier Hermine, Nicolas Boissel, Vahid Asnafi; Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL. Blood 2023; 141 (11): 1353–1358. doi: https://doi.org/10.1182/blood.2022017755 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBlood Search Subjects: Clinical Trials and Observations, Lymphoid Neoplasia, Pediatric Hematology TO THE EDITOR: Among hematologic malignancies, T-cell acute lymphoblastic leukemia (T-ALL) represents a class of aggressive tumors with dismal clinical outcome in cases of relapsed or refractory disease. Although the intensification of multiagent chemotherapy protocols has dramatically improved prognosis, refractory and relapsed cases are clinically challenging because of limited therapeutic options.1,2 p53 is a transcription factor and a master tumor suppressor gene frequently altered in cancer.3 In contrast to carcinomas and other hematologic malignancies, TP53 alterations (TP53Alt), encompassing mutations (TP53Mut), and/or pan-exon deletions (TP53Del) are remarkably rare at diagnosis in T-ALL, and their clinical implication remains elusive.4-6 Critically, TP53Alt have been reported to be acquired in up to 20% of the relapsed T-ALL cases, where they convey a deleterious prognosis.7-9 Here, we produce the first... References 1.Desjonquères A, Chevallier P, Thomas X, et al. Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood Cancer J. 2016;6(12):e504-510.Google ScholarCrossrefSearch ADS PubMed 2.Bhojwani D, Pui C-H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14(6):e205-217.Google ScholarCrossrefSearch ADS PubMed 3.Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20(8):471-480.Google ScholarCrossrefSearch ADS PubMed 4.Kawamura M, Ohnishi H, Guo SX, et al. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res. 1999;23(2):115-126.Google ScholarCrossrefSearch ADS PubMed 5.Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, et al. Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood. 2013;122(1):74-82.Google ScholarCrossrefSearch ADS PubMed 6.Stengel A, Schnittger S, Weissmann S, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124(2):251-258.Google ScholarCrossrefSearch ADS PubMed 7.Richter-Pechańska P, Kunz JB, Hof J, et al. Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer J. 2017;7(2):e523-531.Google ScholarCrossrefSearch ADS PubMed 8.Hof J, Kox C, Groeneveld-Krentz S, et al. NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia. Haematologica. 2017;102(7):e249-e252.Google ScholarCrossrefSearch ADS PubMed 9.Diccianni MB, Yu J, Hsiao M, et al. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood. 1994;84(9):3105-3112.Google ScholarCrossrefSearch ADS PubMed 10.Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31(34):4333-4342.Google ScholarCrossrefSearch ADS 11.Bond J, Marchand T, Touzart A, et al. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica. 2016;101(6):732-740.Google ScholarCrossrefSearch ADS PubMed 12.Asnafi V, Beldjord K, Boulanger E, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003;101(7):2693-2703.Google ScholarCrossrefSearch ADS PubMed 13.Yoon S, Xuan Z, Makarov V, Ye K, Sebat J. Sensitive and accurate detection of copy number variants using read depth of coverage. Genome Res. 2009;19(9):1586-1592.Google ScholarCrossrefSearch ADS PubMed 14.Simonin M, Lhermitte L, Dourthe M-E, et al. IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL. Blood. 2021;137(12):1690-1694.Google ScholarCrossrefSearch ADS PubMed 15.MacDonald JR, Ziman R, Yuen RK, Feuk L, Scherer SW. The Database of Genomic Variants: a curated collection of structural variation in the human genome. Nucleic Acids Res. 2014;42(Database issue):D986-D992.Google ScholarPubMed 16.Petit A, Trinquand A, Chevret S, et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood. 2018;131(3):289-300.Google ScholarCrossrefSearch ADS PubMed 17.Bond J, Touzart A, Leprêtre S, et al. DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica. 2019;104(8):1617-1625.Google ScholarCrossrefSearch ADS PubMed 18.Simonin M, Schmidt A, Bontoux C, et al. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. J Hematol Oncol. 2021;14(1):74-80.Google ScholarCrossrefSearch ADS PubMed 19.Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2016;8(5):8921-8946.Google ScholarCrossrefSearch ADS 20.Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199-212.Google ScholarCrossrefSearch ADS PubMed 21.Lambert JMR, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009;15(5):376-388.Google ScholarCrossrefSearch ADS PubMed 22.Bykov VJN, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8(3):282-288.Google ScholarCrossrefSearch ADS PubMed 23.Cluzeau T, Sebert M, Rahmé R, et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol. 2021;39(14):1575-1583.Google ScholarCrossrefSearch ADS PubMed 24.Demir S, Boldrin E, Sun Q, et al. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(1):170-181.Google ScholarCrossrefSearch ADS PubMed 25.Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39(14):1584-1594.Google ScholarCrossrefSearch ADS 26.Mishra A, Tamari R, DeZern AE, et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022;40(34):3985-3993.Google ScholarCrossrefSearch ADS PubMed © 2023 by The American Society of Hematology2023 © 2023 by The American Society of Hematology2023 You do not currently have access to this content. Sign in via your Institution